bluebird bio (NASDAQ:BLUE – Free Report) had its price objective cut by Bank of America from $4.00 to $3.00 in a research note published on Thursday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.
Several other analysts have also recently commented on BLUE. Robert W. Baird dropped their price target on bluebird bio from $7.00 to $6.00 and set an outperform rating for the company in a research report on Thursday. Royal Bank of Canada reiterated a sector perform rating and set a $4.00 price target on shares of bluebird bio in a research report on Thursday. Barclays dropped their price target on bluebird bio from $8.00 to $4.00 and set an overweight rating for the company in a research report on Thursday. Finally, JPMorgan Chase & Co. cut bluebird bio from an overweight rating to a neutral rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, bluebird bio presently has a consensus rating of Hold and a consensus target price of $4.74.
Check Out Our Latest Analysis on BLUE
bluebird bio Price Performance
Hedge Funds Weigh In On bluebird bio
Several large investors have recently modified their holdings of BLUE. Ghisallo Capital Management LLC acquired a new position in shares of bluebird bio in the 4th quarter valued at $4,347,000. Vestal Point Capital LP acquired a new position in bluebird bio during the 4th quarter worth about $2,967,000. Vanguard Group Inc. lifted its stake in bluebird bio by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after acquiring an additional 1,723,081 shares in the last quarter. HBK Investments L P acquired a new position in bluebird bio during the 4th quarter worth about $2,070,000. Finally, AQR Capital Management LLC lifted its stake in bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock worth $1,223,000 after acquiring an additional 1,013,144 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Featured Articles
- Five stocks we like better than bluebird bio
- What Are Dividend Contenders? Investing in Dividend Contenders
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Following Congress Stock Trades
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.